Skip to main content Skip to section navigation Skip to footer
Careers
Codexis, Inc. Corporate Page
  • About Us
    • Overview
    • Culture
    • Our People
    • Management Team
    • Board of Directors
    • Strategic Advisory Board
    • Sustainability
  • Services
    • Overview
    • Pharmaceutical Biocatalysis
    • RNA Manufacturing
  • Technology
    • CodeEvolver® Platform
    • ECO Synthesis™ Technology
  • Technical Content
  • Newsroom
    • Overview
    • In The News
    • Media Assets
  • Investors
    • Overview
    • News & Events
    • Presentations
    • Company Info
    • Financial Info
    • Stock Data
    • SEC Filings
    • Corporate Governance
  • Contact
  • chevron_leftCareers

Access our TIDES USA 2025 Investor Recap Call

View Replay

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Overview
    • Press Releases
    • IR Calendar
    • Email Alerts
    • TIDES US
  • Presentations
  • Company Info
    • Overview
    • Management Team
    • Contacts
    • FAQ
  • Financial Info
    • Overview
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • Quote and Chart
    • Historical Data
    • Analyst Coverage
  • SEC Filings
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Corporate Governance
    • At-a-Glance
    • Board of Directors
    • Board Committees
    • Governance Documents
    • Codexis Ethics Helpline
  • News & Events

  • Overview
  • Press Releases
  • IR Calendar
  • Email Alerts
  • TIDES US
Oct 20, 2022 4:05 pm EDT
Codexis to Report Third Quarter 2022 Financial Results on November 3
Read More
Oct 3, 2022 8:00 am EDT
Codexis Announces Appointment of Kevin Norrett as Chief Operating Officer
Read More
Oct 3, 2022 8:00 am EDT
Codexis Announces Appointment of Rahul Singhvi, Sc.D., to Board of Directors
Read More
Sep 14, 2022 4:05 pm EDT
Codexis’ 2022 Protein Engineering Forum Showcases Recent Industry Success and Emerging Innovations in the Field
Read More
Aug 4, 2022 4:05 pm EDT
Codexis Reports Second Quarter 2022 Financial Results
Read More
Aug 2, 2022 4:05 pm EDT
Codexis and Molecular Assemblies Announce Execution of Commercial License and Enzyme Supply Agreement for Optimized TdT Enzyme for Enzymatic DNA Synthesis
Read More
Jul 18, 2022 4:05 pm EDT
Codexis Announces CEO Transition Effective August 9, 2022
Read More
Jul 14, 2022 4:06 pm EDT
Codexis Announces Agreement with Pfizer to Supply Enzyme for the Manufacture of PAXLOVID™ (nirmatrelvir tablets; ritonavir tablets)
Read More
Jul 14, 2022 4:05 pm EDT
Codexis Announces Preliminary Second Quarter 2022 Results and Updates Guidance
Read More
Jun 17, 2022 8:00 am EDT
Codexis Announces the Publication of Research Demonstrating Proof of Concept for Chemoenzymatic Site-Selective Bioconjugation of Native Peptides
Read More
  • Previous Pagechevron_left
  • Page 1
  • …
  • Page 5
  • Page 6
  • Page 7
  • Page 8
  • Page 9
  • Page 10
  • Page 11
  • Page 12
  • Page 13
  • Page 14
  • …
  • Page 26
  • Next Pagechevron_right
rss_feed News RSS
  • emailEmail Alerts
  • location_cityCompany Profile
  • contact_pageContacts
  • rss_feedRSS News Feed

Headquarters

200 Penobscot Drive
Redwood City, California
94063

Contact Us

©2025 Codexis, Inc. All Rights Reserved.
  • Sitemap
  • Terms of Sale
  • Trademarks
  • Terms of Use
  • Privacy
  • Accessibility Statement
  • Disclaimer
  • Patents
  • Events
  • Careers